NCT00139386View on ClinicalTrials.gov

Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

1,119

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2012

Conditions
HypertensionCoronary Artery Disease
Interventions
DRUG

Candesartan

Candesartan Cilexetil (4-12 mg per day)

Trial Locations (1)

860-8556

Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto

All Listed Sponsors
collaborator

The 4C trial bureau

UNKNOWN

collaborator

Japan Heart Foundation

OTHER

lead

Kumamoto University

OTHER

NCT00139386 - Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial | Biotech Hunter | Biotech Hunter